Growth factors, their receptors and the kinases behind them
Growth factors tell cells to divide, move or survive; most act through receptor tyrosine kinases and a few shared kinase chains, many of them drug targets.
Key facts
- Most growth factors bind a receptor tyrosine kinase, which activates two main chains: RAS–RAF–MEK–ERK (the MAP kinase pathway) and PI3K–AKT–mTOR.
- Examples: EGF and HER2, PDGF (from platelets, for wound repair and fibrosis), FGF, VEGF and placental growth factor (PlGF, for new vessels), IGF-1 and its receptor (growth hormone's mediator), and HGF with its receptor c-MET.
- c-KIT (CD117) is the receptor for stem cell factor; activating mutations drive gastrointestinal stromal tumours and systemic mastocytosis, and imatinib blocks it.
- Insulin receptor substrate 1 (IRS-1) is phosphorylated by the insulin receptor and recruits PI3K; its phosphorylation on serine in obesity is one mechanism of insulin resistance.
- mTOR activates p70 S6 kinase, which phosphorylates ribosomal protein S6 and boosts protein synthesis and cell growth; sirolimus (rapamycin) blocks mTOR.
Growth factors at a glance
| Factor | Receptor | Main job | Disease link |
|---|---|---|---|
| EGF | EGFR (ERBB1) | Epithelial growth and repair | EGFR-mutant lung cancer |
| HER2 (no ligand of its own) | ERBB2, partner of other ERBBs | Amplifies ERBB signals | HER2-amplified breast and gastric cancer |
| VEGF, PlGF | VEGFR1/2 | New blood vessels | Tumour angiogenesis, wet macular degeneration, pre-eclampsia (sFlt-1 excess) |
| PDGF | PDGFR | Fibroblast and smooth-muscle growth, wound repair | Fibrosis, some stromal tumours |
| Stem cell factor | c-KIT (CD117) | Mast cells, germ cells, pacemaker cells of the gut | GIST, systemic mastocytosis |
| HGF (scatter factor) | c-MET | Cell scattering and movement | MET-altered lung cancer |
In detail
- ERK carries growth signals; JNK and p38 are stress-activated kinases switched on by cytokines, ultraviolet light and osmotic stress.
- GSK-3 keeps glycogen synthase inactive; insulin, through AKT, inhibits GSK-3 so glycogen is made. GSK-3 also controls β-catenin in the Wnt pathway.
- Hypoxia-inducible factor 1α (HIF-1α) is destroyed when oxygen is normal, through the VHL protein; in hypoxia it accumulates and switches on erythropoietin, VEGF and glycolysis genes.
- TGF-β slows the growth of epithelial cells and drives fibrosis; many cancers escape its brake.
- HGF, also called scatter factor, makes epithelial cells separate and move; MET amplification or mutation occurs in some lung cancers.
- Also called
- c-KIT, c-MET, IGF-1R and VEGF, MAPK, mTOR and HIF
What breaks, and the disease it causes
- Activating c-KIT (or PDGFRA) mutation→ the receptor signals without ligand in the gut's pacemaker cells: gastrointestinal stromal tumour, which responds to KIT inhibitors. Gastrointestinal stromal tumour (GIST) →
- Loss of VHL→ HIF is never destroyed: VEGF and erythropoietin are switched on, giving vascular clear-cell kidney tumours. Renal cell carcinoma →
- Placenta releases excess sFlt-1→ free VEGF and PlGF are trapped and the maternal endothelium suffers: hypertension and proteinuria. Preeclampsia →
Clinical notes
- Loss of VHL keeps HIF active and causes clear-cell renal carcinoma and haemangioblastomas.
- A high ratio of soluble Flt-1 (a VEGF trap) to PlGF in the mother's blood helps predict pre-eclampsia.
- Kinase inhibitors and monoclonal antibodies against these receptors (anti-EGFR, anti-HER2, anti-VEGF, KIT inhibitors) are central to modern cancer treatment.
Common traps
- Each growth factor has its own private pathway: most converge on the same two chains (MAPK and PI3K–AKT–mTOR); what differs is the receptor, the cell and the job.
- HER2 is activated by its own ligand: HER2 has no known ligand; it is the preferred partner of other ERBB receptors, and amplification lets it signal by mass.
- TGF-β is a growth factor, so it always promotes tumours: in normal epithelium it slows division; tumours escape its brake, and later it also promotes fibrosis and invasion.
- HIF is controlled at the gene level: it is made all the time but destroyed in normal oxygen via VHL; hypoxia or VHL loss lets it accumulate.
Test yourself
Think of the answer, then tap the question to see it.
Which two signalling chains do most growth-factor receptors activate?
RAS–RAF–MEK–ERK (MAP kinase) and PI3K–AKT–mTOR.
What happens to HIF-1α when oxygen is low?
It is no longer destroyed via VHL, so it accumulates and switches on genes such as erythropoietin and VEGF.
A patient has a gastric wall tumour that stains strongly for CD117 (c-KIT). Why does a KIT kinase inhibitor shrink it?
Most GISTs carry an activating KIT (or PDGFRA) mutation that signals without ligand; blocking the receptor's kinase removes the growth signal the tumour depends on.
A pregnant woman at 32 weeks has new hypertension and a high sFlt-1/PlGF ratio. What is the mechanism?
The stressed placenta releases soluble Flt-1, which traps VEGF and PlGF; the maternal endothelium loses this survival signal, leading to vasoconstriction, hypertension and proteinuria (pre-eclampsia).
Connections
Educational information, not medical advice. For any symptom, see a health professional.
Sources: KIT: Mast/stem cell growth factor receptor Kit (human) (UniProt, 2026); MET: Hepatocyte growth factor receptor (human) (UniProt, 2026); HIF1A: Hypoxia-inducible factor 1-alpha (human) (UniProt, 2026); RPS6KB1: Ribosomal protein S6 kinase beta-1 (human) (UniProt, 2026); IRS1: Insulin receptor substrate 1 (human) (UniProt, 2026).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
